sibutramine + olanzapine

**Sibutramine + olanzapine** is a combination of two small molecule pharmaceuticals: sibutramine, a norepinephrine and serotonin reuptake inhibitor primarily used as an anti-obesity agent, and olanzapine, a second-generation (atypical) antipsychotic. Olanzapine is known to cause weight gain, likely through antagonism of serotonergic (5-HT2A/2C), dopaminergic (D2), histaminergic (H1), muscarinic, and adrenergic receptors. Sibutramine, acting mainly as a norepinephrine and serotonin reuptake inhibitor, induces weight loss by enhancing satiety and increasing energy expenditure. Experimental studies and small clinical trials have examined the combination to counteract olanzapine-associated weight gain in patients with schizophrenia or related disorders; sibutramine may reduce the hyperphagic drive induced by olanzapine but does not affect the antipsychotic properties[1][3]. This combination is not an established commercial product and does not have a unique brand or proprietary name.